Aeglea Biotherapeutics

28 articles with Aeglea Biotherapeutics

• 

  New CEOs Named in BioSpace’s Biopharma Movers and Shakers for July 23

  7/23/2018

  It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.

• Gemini Therapeutics Strengthens Senior Leadership Team with Key Appointments and Promotion

  5/30/2018

  Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.

• 

  Aeglea BioTherapeutics Updates Phase I/II Trial Data

  3/13/2018

  Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

• Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase I/II Trial with Pegzilarginase (AEB1102)

  11/29/2017

  Clinical agreement reached with FDA to enable pediatric dosing.

• Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

  11/8/2017

  On September 30, 2017, Aeglea had available cash, cash equivalents and marketable securities of $55.7 million.

• Aeglea BioTherapeutics Inks Clinical Collaboration with Merck

  10/16/2017

  Aeglea and Merck will evaluate the combination of Aeglea's AEB1102 with Merck’s anti-PD-1 therapy, KEYTRUDA for the treatment of patients with small cell lung cancer.

• Aeglea Doses Two Patients In Repeat Dose Part Of Phase I/II Clinical Trial For The Treatment Of Arginase 1 Deficiency

  9/6/2017

• Aeglea Appoints James Wooldridge, M.D. As Chief Medical Officer

  7/11/2017

• Aeglea Prices Public Offering Of Common Stock

  6/6/2017

• Aeglea Announces Proposed Public Offering Of Common Stock

  6/6/2017

• Aeglea Provides AEB1102 Program And Corporate Update

  5/23/2017

• Aeglea Provides Corporate Update And Reports First Quarter 2017 Financial Results

  5/9/2017

• Everything's Bigger in Texas: Aeglea Quickly Growing into Leading Austin Biotech

  9/14/2016

• Aeglea Announces Closing Of Initial Public Offering And Partial Exercise Of The Underwriters’ Option

  4/13/2016

• Aeglea Appoints Dr. Anthony Quinn To Board Of Directors

  3/15/2016

• Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Hematological Malignancies

  3/15/2016

• Top 20 Life Science Startups to Watch in the U.S.

  1/28/2016

• Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Arginase I Deficiency

  1/7/2016

• What You Need to Know About Aeglea

  12/2/2015

• Aeglea Doses First Patient In Phase I Study Of AEB1102 For Treatment Of Solid Tumors

  10/26/2015